III期HIMALAYA研究中曲美木单抗联合度伐利尤单抗治疗不可切除肝细胞癌的患者报告结局
III期HIMALAYA研究纳入1171例不可切除肝细胞癌患者,随机分配至STRIDE方案组(393例)、度伐利尤单抗组(389例)或索拉非尼组(389例)。患者报告结局显示,STRIDE和度伐利尤单抗在总体健康状况/生活质量、功能及疾病相关症状方面较索拉非尼带来具有临床意义的获益,且未观察到任一治疗组出现具有临床意义的恶化。
要点
- STRIDE和度伐利尤单抗组在总体健康状况/生活质量、躯体功能、疲乏、食欲丧失和腹痛的恶化时间数值上长于索拉非尼组。
- STRIDE和度伐利尤单抗组在总体健康状况/生活质量、角色、情感和社会功能及疾病相关症状方面获得临床意义改善的可能性大于索拉非尼组。
- 恶心和腹部肿胀的恶化时间在STRIDE组数值上长于索拉非尼组。
核心结论
- 与索拉非尼相比,STRIDE和度伐利尤单抗在不可切除肝细胞癌患者中与具有临床意义的、以患者为中心的总体健康状况/生活质量、功能和症状获益相关。
- 这些发现支持STRIDE方案相较于索拉非尼在反映全球不可切除肝细胞癌人群的多样化人群中的获益。
研究设计与样本
- III期HIMALAYA研究(ClinicalTrials.gov标识符:NCT03298451),患者随机接受STRIDE、度伐利尤单抗或索拉非尼治疗。
- 共1171例参与者被随机分配至STRIDE组(n=393)、度伐利尤单抗组(n=389)或索拉非尼组(n=389),并可进行患者报告结局评估。
- 患者报告结局为预先计划的次要终点,采用欧洲癌症研究与治疗组织30项生活质量问卷及18项肝细胞癌模块进行评估。
主要发现
- 各治疗组患者报告结局的依从率在基线时>77%,总体>70%。
- 基线评分在各治疗组间相当。
- 总体健康状况/生活质量、躯体功能、疲乏、食欲丧失和腹痛的恶化时间在STRIDE和度伐利尤单抗组数值上长于索拉非尼组。
- 任一治疗组均未观察到患者报告结局具有临床意义的恶化。
- 恶心和腹部肿胀的恶化时间在STRIDE组数值上长于索拉非尼组;总体健康状况/生活质量、角色、情感和社会功能及疾病相关症状获得临床意义改善的可能性在STRIDE和度伐利尤单抗组大于索拉非尼组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the phase III HIMALAYA study (ClinicalTrials.gov identifier: NCT03298451) in unresectable hepatocellular carcinoma (uHCC), the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen significantly improved overall survival versus sorafenib, and durvalumab monotherapy was noninferior to sorafenib. Patient-reported outcomes (PROs), a secondary outcome from HIMALAYA, are reported here. METHODS: Participants were randomly assigned to receive STRIDE, durvalumab, or sorafenib. PROs were assessed (preplanned secondary outcome) using the European Organization for Research and Treatment of Cancer 30-item Quality of Life Questionnaire and the 18-item HCC module. Time to deterioration (TTD), change from baseline and improvement rate in global health status/quality of life (GHS/QoL), functioning, and disease-related symptoms were analyzed. RESULTS: In total, 1,171 participants were randomly assigned to STRIDE (n = 393), durvalumab (n = 389), or sorafenib (n = 389) and were evaluable for PRO assessments. Across treatment arms, compliance rates for PROs were >77% at baseline and >70% overall. Baseline scores were comparable across treatment arms. TTD in GHS/QoL, physical functioning, fatigue, appetite loss, and abdominal pain was numerically longer for both STRIDE and durvalumab versus sorafenib. Clinically meaningful deterioration in PROs was not observed in any treatment arm. However, TTD in nausea and abdominal swelling was numerically longer for STRIDE versus sorafenib, and the likelihood of clinically meaningful improvement in GHS/QoL, role, emotional and social functioning, and disease-related symptoms was greater with STRIDE and durvalumab versus sorafenib. PROs with STRIDE and durvalumab were generally similar. CONCLUSION: Compared with sorafenib, STRIDE and durvalumab were associated with clinically meaningful, patient-centered GHS/QoL, functioning, and symptom benefits in people with uHCC. These findings support the benefits of the STRIDE regimen compared with sorafenib for a diverse population reflective of the global uHCC population.
引用
- Sangro B, Galle PR, Kelley RK, et al. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2024. PMID: 38805668. doi:10.1200/JCO.23.01462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。